[Information provided by:
ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]
|NCT02663271 : TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma|
|Ages||Min: 22 Years Max: N/A|
- Histologically confirmed GBM, WHO grade IV. GBM variants and secondary GBM are allowed
in any recurrence (including multiple) and have been treated with radiation and
- Unequivocal evidence of tumor progression during prior bevacizumab treatment per RANO
- Patient is a candidate for, and agrees to proceed with additional bevacizumab
- Male or female at least 22 years of age or older.
- Karnofsky Performance Scale (KPS) = 60%.
- Planned treatment with TTFields therapy.
- Women of childbearing potential must have a negative serum or urine pregnancy test
within 14 days of treatment.
- Participants of childbearing/reproductive potential must use effective contraception.
- Participants must be able to understand and willing to comply with protocol
requirements as assessed by the investigator.
- Signed informed consent according to institutional guidelines prior to registration.
- Inability to undergo brain MRI due to medical or personal reasons.
- Currently receiving investigational agents that are intended as treatments of
- Skull defect such as missing bone or bullet fragments.
- Uncontrolled intercurrent illness including, but not limited to symptomatic congestive
heart failure, unstable angina pectoris, heart attack within the previous 12 months,
stroke (except for TIA) within the previous 6 months, or psychiatric illness/social
situations that would limit compliance with study requirements.
- Intracranial hemorrhage except for tumor associated micro hemorrhage.
- Women who are pregnant or breastfeeding.
- Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, vagus
nerve stimulator, and other implanted electronic devices in the brain or the spinal
- Tumor located entirely in the infratentorium.
- History of hypersensitivity to hydrogel.
|Links||Permanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02663271
| Link to official Clinicaltrials.gov listing